CME
Expires

CME Program - Improving TAVR Outcomes During COVID-19: The Role Virtual Proctoring & CME

 

In this webcast, experts will discuss virtual proctoring, program development, and healthcare resources to combat COVID-19 versus providing essential cardiovascular care for TAVR patients.

CME ACCREDITATION AND DESIGNATION

CME logoThe Cardiovascular Research Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cardiovascular Research Foundation designates this activity for a maximum of AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Documentation of awarded credit is provided for participants in exchange for completed activity evaluations. Evaluation by questionnaire will address content, presentation effectiveness, possible bias, and future educational needs.

To obtain CME credit for this activity, participants must review all CME information, view all presentations in their entirety, and complete the Activity Evaluation Form. If you have any questions, please contact Joe Heard at jheard@crf.org .

 

 

By the end of this program, participants should be able to:

• Describe how COVID-19 has impacted the way physicians care for TAVR patients
• Discuss virtual proctoring and its role during COVID-19
• Review pre, peri, and post procedural clinical pathways during COVID-19

 

 

This educational activity is designed for interventional cardiologists, clinical cardiologists, and other healthcare professionals involved in the management of patients with coronary artery disease.

 

 

It is the policy of the Cardiovascular Research Foundation to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational activities. Commercial support from industry does not influence educational content, faculty selection, and/or faculty presentations, and therefore, does not compromise the scientific integrity of the educational activity.

Discussion of off-label product usage is made at the sole discretion of the faculty. Off-label product discussion and usage is not endorsed by the Cardiovascular Research Foundation or the course directors of this activity.

All Planners (Directors, Co-Directors and Chairs) and Faculty participating in continuing medical education activities sponsored by the Cardiovascular Research Foundation are required to disclose to the activity audience any real or apparent conflicts of interest related to the content of their presentations. Anyone in noncompliance with this policy is not permitted to participate in this activity.

KEY: (G/R) Grant Support/Research Contract (C/H/S) Consultant Fee/Honoraria/Speaker’s Bureau (E/S/O) Equity/Stock(s)/Options (R/I) Royalty/Intellectual Property Rights (S) Salary/Salary Support (O) Other Financial Benefit

Planners

Jeroen Bax, MD Nothing to Disclose

David Wood, MD – (G/R) Edwards Lifesciences, Medtronic, Abbott Vascular (C/H/S) Edwards Lifesciences

Faculty

Kentaro Hayashida, MD – (G/R) Edwards Lifesciences (C/H/S) Edwards Lifesciences

Sandra Lauck, PhD – (C/H/S) Edwards Lifesciences

Bernard Prendergast, MD –(G/R) Edwards Lifesciences (C/H/S)  Edwards Lifesciences

Athenas Poppas, MD – (C/H/S) GE

Janarthanan Sathananthan, MD – (C/H/S) Edwards Lifesciences; Medtronic; Boston Scientific

 

Content Reviewer(s):
Gary S. Mintz, MD – Nothing to disclose
Tricia Rawh - Nothing to disclose
Joe Heard, MHA – Nothing to disclose
 

 

 

This program is sponsored by the Cardiovascular Research Foundation and supported through an unrestricted grant from Edwards Lifesciences. The Cardiovascular Research Foundation ensures that its programs are educational and meet the needs of the target audience. This program was developed without influence from commercial supporters.

 

 

 

We Recommend